NHS in England and Wales might soon start offering the anti-wrinkle drug, Botox for patients who suffer from chronic migraines, according to a draft of guidelines by the National Institute for Health and Clinical Excellence (NICE).

According to estimates, about 700,000 people in the UK have chronic migraine and require such medicines. NICE has recommended providing Botox when other medicines have failed. The recommendation has been welcomed by the Migraine Trust.

Migraines is a condition in which patients suffer extreme headaches with nausea and it makes them sensitive to noise and light. The patients usually have headaches on at least 15 days a month. Botox was approved by the regulators for treatment of chronic migraine in 2010 in the UK. NICE has asked the manufacturer for some proofs and it now believes that the drug must be used for some patients.

"Chronic migraines are extremely debilitating and can significantly affect a person's quality of life. We are pleased that the committee has been able to recommend Botox as a preventative therapy for those adults whose headaches have not improved despite trying at least three other medications and whose headaches are not caused by medication overuse," said Prof Carole Longson, the director of the health technology evaluation centre at NICE.

The final guidelines by the NICE are expected to be published in June.